XERS
Xeris Biopharma Holdings, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Xeris Biopharma Holdings, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
No other changes.
No other changes.
Last report4 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Annual filing, covered
10-K parsed · Mar 2 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 2 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
Xeris Biopharma Holdings, Inc.
10.47
No thesis.
−9.25%
vs ±14.3% implied · ×0.65
shaded = implied · ▲▼ = realized
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Xeris Biopharma Holdings, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Xeris Biopharma Holdings, Inc.'s 6 closest co-movers, none share that code.
—
—
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $115.0M | 13.25% | +12.20% |
| D. E. Shaw | $61.8M | 7.12% | +0.20% |
| Vanguardindex-like | $58.1M | 6.69% | +5.15% |
| State Streetindex-like | $38.2M | 4.40% | +3.51% |
| Geodeindex-like | $37.4M | 4.30% | +9.96% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $115.0M | 13.25% | +12.20% |
| D. E. Shaw | $61.8M | 7.12% | +0.20% |
| Vanguardindex-like | $58.1M | 6.69% | +5.15% |
| State Streetindex-like | $38.2M | 4.40% | +3.51% |
| Geodeindex-like | $37.4M | 4.30% | +9.96% |
Bull2
Bear2
Expected move
Inputsspot 10.35exp Nov 20ATM strike 10ATM straddle 1.83IV 103%